Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome.
OBJECTIVE
To evaluate the relationship between antiandrogen withdrawal and change in prostate-specific antigen (PSA) when the antiandrogen in question is other than flutamide.


METHODS
Presented is a case of a patient in whom the antiandrogen casodex was discontinued after clinical progression despite combined androgen blockade.


RESULTS
A transient decline in serum PSA was observed after casodex withdrawal.


CONCLUSIONS
The relationship between antiandrogen withdrawal and a change in PSA may be a general phenomenon, not unique to flutamide.
Small
E J
EJ
Department of Medicine, University of California, San Francisco.
Carroll
P R
PR
D000726:Androgen Antagonists; D000813:Anilides; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D017430:Prostate-Specific Antigen / Q000097:blood*; D013375:Substance Withdrawal Syndrome / Q000097:blood*; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen